GlassScriptPhysician profile
Meloni N Carter
NPI 1477502748
$4,515.93
in general payments reported to CMS, 2019-2025
32 companies · $1,593 in 2025
The $1,593 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.69 · 2022: $302 · 2023: $896 · 2024: $1,680 · 2025: $1,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,103 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,103.48 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $860.60 | 2022-2025 | |
| Glaxosmithkline, LLC. | $583.45 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $531.83 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $488.53 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $348.50 | 2021-2025 | |
| Lilly USA, LLC | $272.63 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Corium, LLC | $178.48 | 2023-2024 | Azstarys |
| Amgen INC. | $161.72 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.14 | 2022-2025 | Xifaxan, Trulance, Relistor |
| Almatica Pharma LLC | $118.41 | 2024-2025 | Loreev Xr |
| Axsome Therapeutics, INC. | $107.47 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $102.56 | 2023-2024 | Myrbetriq, Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.76 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $56.35 | 2024 | Voquezna |
| Mylan Specialty L.P. | $54.73 | 2023-2024 | Yupelri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $53.35 | 2025 | Rexulti |
| Exact Sciences Corporation | $48.82 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.97 | 2025 | |
| Lundbeck LLC | $36.43 | 2025 | Rexulti |
| Horizon Therapeutics Plc | $36.37 | 2023 | Krystexxa |
| Neurocrine Biosciences, INC. | $26.71 | 2022 | |
| Shield Therapeutics INC | $20.43 | 2025 | |
| Collegium Pharmaceutical, INC. | $19.72 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $18.95 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.90 | 2024 | Eliquis |
| Ibsa Pharma INC. | $17.39 | 2023 | Tirosint, Licart |
| Abbott Laboratories | $17.36 | 2022 | |
| Merck Sharp & Dohme LLC | $17.20 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Medtronic, INC. | $16.00 | 2025 | Venaseal |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.33 | 2025 | Jardiance |
| Sumitomo Pharma America, INC. | $14.65 | 2025 | Gemtesa |
| Ironshore Pharmaceuticals INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meloni Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.